AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04334772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendon Microelectrolysis
Description: three applications of direct current at 600 µA interrupted by intervals of 30 seconds between application in the tendon of the shortened hamstrings.
Study NCT04334772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: 5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
Study NCT04334772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: 5 sets of passive static hamstring stretches using the straight leg extension (SLR) test for a time of 30 seconds and interval of 30 seconds for each
Study NCT02568800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Cefepime Infusion
Description: Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
Study NCT03166735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: once daily
Study NCT03166735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study NCT00791960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimenhydrinate
Description: single dose, 25mg, IV, diluted in 9.5mL normal saline.
Study NCT00791960 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose, 10 mL normal saline, IV
Study NCT03717818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Psychiatric Management - Brief
Description: specific interventions as defined by Gunderson and Links (2014)
Study NCT03717818 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: treatment as usual
Description: non-specific intervention
Study NCT03797014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
Study NCT01292746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia MLS
Description: The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
Study NCT04450641 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GuessWhat Mobile Application
Description: The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
Study NCT00918138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 5 mg, once daily, 4 weeks
Study NCT00918138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, 1500 mg, once daily, 4 weeks
Study NCT04450641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GuessWhat Mobile Application
Description: The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
Study NCT04499638 — intervention group
Intervention type: DEVICE
Intervention: Peripheral vascular catheters
Description: Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal
Study NCT05221593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 400 mg tablet in controlled released formula
Study NCT02842541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBI-031
Study NCT00918138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Tablets, Oral, 1500 mg, once daily, 4 weeks
Study NCT00918138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Metformin XR
Description: Tablets, Oral, 0 mg, once daily, 4 weeks
Study NCT00918138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin XR
Description: Tablets, Oral, 500 mg, once daily, 4 weeks
Study NCT01896661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics
Description: Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
Study NCT01896661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Channel Blockers
Description: Amlodipine 10 mg daily, taking in the morning
Study NCT03241589 — intervention group
Intervention type: OTHER
Intervention: Direct to patient facing mobile apps introduction
Description: VA employees and Veterans begin use of OCC's direct to patient facing mobile app.
Study NCT04189640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure. If the VAS score will be ≥ 4, 0.5 mg/ kg tramadol IV will be administered.
Study NCT00918346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015%
Description: Eye drops, 0.015 mg/ml, once daily to affected eye(s)
Study NCT01761994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulation with nafamostat mesilate
Description: Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
Study NCT01761994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation with nafamostat mesilate
Description: Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
Study NCT03456180 — intervention group
Intervention type: DEVICE
Intervention: Haemoadsorption with Cytosorb cartridge
Description: microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
Study NCT00159380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Description: 500mg
Study NCT00159380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 2ml
Study NCT01209806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simethicone
Description: 400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
Study NCT03049072 — intervention group
Intervention type: RADIATION
Intervention: Protons and Carbon Ions
Study NCT03790072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OmnImmune®
Description: infusion of OmnImmune® (expanded gamma delta T lymphocytes)
Study NCT01089218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral amoxicillin/clavulanate 1g (875/125mg)
Description: oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
Study NCT01089218 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: control
Description: no intervention with the same procedure of FB
Study NCT00969488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats).
Study NCT00969488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High protein diet
Description: INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats).
Study NCT02403960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: the patients used probiotic tablets in addition to scaling and root planning
Study NCT02403960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the patients used placebo tablets in addition to scaling and root planning
Study NCT02593461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daifert
Study NCT02593461 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Study NCT02713945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Experimental drug administrated orally
Study NCT02713945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for the control group
Study NCT02242760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 2%
Description: Applied topically twice daily
Study NCT02242760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Applied topically daily
Study NCT02242760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Applied topically twice and once daily
Study NCT01421069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Subjects aged \<18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).~Subjects aged greater than or equal to 18 years or >62 kg will receive etanercept SC at a dose of 50 mg QW.
Study NCT02491216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
Study NCT04119401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: doppler-guided hemorrhoidal artery ligation
Description: Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations.
Study NCT04119401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Finger-guided hemorrhoidal artery ligation
Description: Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group
Study NCT00625014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol 3 mg/day for 8 days
Study NCT03238352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium oxalate
Description: Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride
Study NCT03238352 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium fluoride
Description: Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)
Study NCT03238352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral rinse containing 0% KOX and 0 ppm fluoride
Study NCT03254940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charge
Description: Text messaging-based study to determine effect of different components on weight loss.
Study NCT00918138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Saxagliptin
Description: Tablets, Oral, 0 mg, once daily, 4 weeks
Study NCT02217787 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-06372865
Description: 7.5 mg as 3 x 2.5 mg tablets single dose
Study NCT01250197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Description: Ophthalmic Solution
Study NCT03413293 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of bacterial infections
Description: Cultures
Study NCT01923649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide 90 mg slow release formulation
Description: Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
Study NCT01923649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for somatuline slow release 90 mg
Study NCT04153929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: Solution for Injection
Study NCT04153929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for Injection
Study NCT04153929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Solution for Injection
Study NCT03663634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytochalasin B use in ICSI handling medium
Description: A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
Study NCT03056586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal pessary
Description: A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
Study NCT00894101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18] FLT
Description: 10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
Study NCT02885597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juanbi pill
Description: 4g, twice a day, 3month, oral
Study NCT02885597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Juanbi pill placebo
Description: 4g, twice a day, 3month, oral
Study NCT02885597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5mg, once a week, 3 month, oral
Study NCT02885597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 5mg, once a week, 3 month, oral
Study NCT02729311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired PLIÉ Program
Description: The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
Study NCT03086837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone based intervention
Description: Participants will receive supporting messages through a mobile phone based intervention.
Study NCT04364425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
Study NCT04364425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: ultrasound guided steroid injection using 1ml of 10mg or 4ml of 40mg triamcinolone acetonide
Study NCT04364425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine hydrochloride
Description: Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
Study NCT04364425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine hydrochloride
Description: Ultrasound guided injection using 4ml of 2% lidocaine hydrochloride (Xylocaine)
Study NCT04364425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Ultrasound guided injection using 15ml or 12 ml of normal saline
Study NCT04364425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Ultrasound guided injection using 15ml or 12 ml of normal saline
Study NCT04263077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: The diamond shape technique, which is a kinesio tape technique, will be used in the lateral epicondyle region. The ends of the kinesiotapes will be applied tension-free without overlapping.
Study NCT04263077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 50% TENSION GROUP
Description: Kinesiotape will be applied to the lateral epicondyle region with 50% tension.
Study NCT04263077 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 75% TENSION GROUP
Description: Kinesiotape will be applied to the lateral epicondyle region with 75% tension.
Study NCT02767154 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A colloid Dextran 40 solution for extracorporeal circulation
Description: The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
Study NCT02729311 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Paired PLIÉ Program
Description: The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
Study NCT00853619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Service based decision support intervention
Description: Delivering CDS via services
Study NCT00853619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service based decision support intervention
Description: Delivering CDS via services
Study NCT00753623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon
Description: ramelteon (8 mg)
Study NCT00753623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramelteon
Description: ramelteon (8 mg)
Study NCT00753623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
Study NCT00753623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
Study NCT01042054 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard optimised recovery protocol.
Description: * Epidural analgesia for the first 48 hours postoperatively.~* Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~* Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~* Optimised recovery protocol followed throughout.